Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in COVID-19 Pneumonia
NCT04344782Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial in COVID-19 pneumonia comparing Bevacizumab with Standard of Care (2 arms). Primary endpoint: Proportion of surviving patients without need for intubation for respiratory support at 14 days. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04344782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344782.